View Older Stories View More Recent Stories

Apr 9, 2018 09:30AM Be The Match BioTherapies Strengthens Partnership with Magenta Therapeutics
Apr 9, 2018 09:00AM Magenta Therapeutics Secures $52 Million in Series C Financing
Apr 9, 2018 08:00AM Generation Bio Strengthens Leadership Team with Appointment of Will McCarthy as Chief Business Officer and Jennifer Elliott, Ph.D., J.D., as Head of Legal Affairs and Intellectual Property
Apr 6, 2018 10:05AM Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors
Apr 5, 2018 08:30AM Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders
Apr 3, 2018 05:18PM Form 4 Atlas Venture Associates For: Apr 03 Filed by: Unum Therapeutics Inc.
Apr 3, 2018 08:30AM Magenta Therapeutics Announces Departure of Chief Operating Officer Bastiano Sanna, Ph.D.
Mar 28, 2018 09:11PM Form 3 Unum Therapeutics, Inc. For: Mar 28 Filed by: Atlas Venture Associates IX, L.P.
Mar 20, 2018 07:00AM Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231
Mar 19, 2018 08:30AM Obsidian Therapeutics to Present at Upcoming Investor Conferences
Mar 15, 2018 08:00AM Obsidian to Present Data on its Destabilizing Domain Technology and Product Programs at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting
Mar 14, 2018 04:31PM Form SC 13D Spero Therapeutics, Inc. Filed by: Atlas Venture Fund X, L.P.
Mar 12, 2018 08:00AM Precision Neuroscience Company Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883
Mar 8, 2018 09:00AM Magenta Therapeutics Strengthens Leadership Team with Promotions, New Hires
Mar 6, 2018 08:00AM Disarm Therapeutics Expands Scientific Advisory Board with Experts in Neurology, Neuropathy, and Axonal Degeneration
Feb 27, 2018 07:00AM Generation Bio Announces $100 Million Series B Financing to Advance GeneWave™ Platform for Re-Dosable Gene Therapy
Feb 22, 2018 07:00AM Surface Oncology Expands Board of Directors
Feb 21, 2018 09:12AM Magenta Therapeutics Hires John Davis, MD, MPH, as Chief Medical Officer
Feb 13, 2018 11:04AM Form SC 13G Spero Therapeutics, Inc. Filed by: Atlas Venture Associates IX, L.P.
Feb 13, 2018 08:00AM Obsidian Therapeutics Presents Data Demonstrating Regulation of Protein Activity with its Next-Generation CAR-T Platform at Keystone Symposium on Emerging Cellular Therapies
Feb 12, 2018 07:00AM Surface Oncology Promotes Jeff Goater to Chief Executive Officer
Feb 12, 2018 06:54AM Form SC 13G/A ZAFGEN, INC. Filed by: Atlas Venture Fund VII L P
Feb 12, 2018 06:54AM Form SC 13G/A Egalet Corp Filed by: Atlas Venture Fund VII L P
Feb 12, 2018 06:54AM Form SC 13G/A Intellia Therapeutics, Filed by: Atlas Venture Fund IX, L.P.
Feb 6, 2018 06:55AM Atlas Venture Announces That Nessan Bermingham Re-Joins as Venture Partner
Feb 5, 2018 04:25PM Form 13F-HR Atlas Venture Associates For: Dec 31
Feb 1, 2018 07:00AM AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases
Jan 23, 2018 08:00AM Disarm Therapeutics Appoints Thomas Engber as Senior Vice President, Head of Neuropharmacology and Translational Sciences
Jan 22, 2018 08:00AM Harbour BioMed Completes Series A+ Round Financing to Accelerate the Development of Clinical Programs and Company Growth
Jan 8, 2018 01:10PM Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology
Jan 4, 2018 07:00AM Atlas Venture Launches Generation Bio
Dec 19, 2017 09:00AM Disarm Therapeutics Appoints Peter Keller Chief Business Officer
Dec 14, 2017 06:00AM Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways
Dec 6, 2017 06:15AM Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products
Nov 15, 2017 07:00AM Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017
Nov 9, 2017 02:10PM Navitor Pharmaceuticals’ Scientific Founder Makes Seminal Discoveries Related to Role of Nutrient Sensors in mTOR Regulation and Activity
Nov 3, 2017 09:14AM Form 13F-HR Atlas Venture Associates For: Sep 30
Nov 1, 2017 07:50PM Form 3 Atlas Venture Associates For: Nov 01 Filed by: Spero Therapeutics, Inc.
Nov 1, 2017 09:01AM Magenta Therapeutics to Present Clinical Results and Preclinical Research at American Society of Hematology (ASH) Annual Meeting
Oct 30, 2017 07:00AM Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies
Oct 26, 2017 08:00AM Magenta Therapeutics Strengthens Leadership Team
Oct 24, 2017 04:01PM Magenta Therapeutics Appoints Alison Lawton, Jeff Albers and Blake Byers to its Board of Directors
Oct 17, 2017 07:00AM Gemini Therapeutics Announces $42.5 Million Series A Financing to Develop Precision Therapeutics in Ophthalmology and Rare Genetic Diseases
Oct 17, 2017 07:00AM Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies
Oct 9, 2017 06:59AM Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine
Oct 3, 2017 08:00AM Cullinan Oncology Secures $150 Million Series A Financing to Build Innovative Development Company
Sep 29, 2017 05:14PM Form SC 13D SYNLOGIC OPERATING CO Filed by: Atlas Venture Fund IX, L.P.
Sep 28, 2017 10:45AM Forbes Names PillPack One of the Next Billion-Dollar Companies
Sep 26, 2017 09:00AM FierceBiotech Names Magenta Therapeutics as one of its “Fierce 15” Biotech Companies of 2017
Sep 19, 2017 07:00AM Disarm Therapeutics Unveils Breakthrough Approach to Treat Patients with Neurological Diseases by Preventing Axonal Degeneration
View More Recent Stories View Older Stories